Clinical research continues to expand through artificial intelligence innovation, regenerative neuroscience programs, and supportive care studies in oncology. Recent developments include new validation data for AI in opioid use disorder treatment, regulatory momentum for a spinal cord injury therapy entering Phase 3 planning, and a new investigator-sponsored cancer center study focused on reducing chemotherapy-related toxicity.
Recent coverage highlighted by Clinical Trial Vanguard showcases how innovation is advancing across addiction medicine, neurology, and oncology supportive care.
Landmark Study Validates AI for Opioid Disorder Treatment
Artificial intelligence is increasingly being integrated into behavioral health and addiction care. A recent study reported that AI tools can help identify substance use disorder behaviors with strong predictive accuracy, potentially enabling earlier intervention and faster treatment referrals. Emerging evidence suggests these systems may improve triage efficiency and support clinicians managing opioid use disorder.
AI-assisted care models may become especially valuable in healthcare settings where addiction specialists are limited or screening rates remain low.
Learn more in Landmark Study Validates AI for Opioid Disorder Treatment.
NervGen’s Successful FDA Meeting Sparks Phase 3 Trial Hope
NervGen Pharma has completed a successful End-of-Phase 2 meeting with the FDA and aligned on its Phase 3 RESTORE study evaluating NVG-291 in chronic tetraplegia caused by spinal cord injury. Reported earlier data showed a mean 3.7-point gain in GRASSP Quantitative Prehension at Week 12 versus 0.4 points on placebo.
The planned registrational study represents an important milestone for regenerative therapies targeting neurological recovery after spinal cord injury.
Further details are available in NervGen’s Successful FDA Meeting Sparks Phase 3 Trial Hope.
Fennec Pharma and University of Arizona Cancer Center Announce Study
Supportive oncology research is also advancing through a new investigator-sponsored Phase I/II study at the University of Arizona Cancer Center evaluating PEDMARK® (sodium thiosulfate injection) in adolescent, young adult, and adult patients receiving cisplatin chemotherapy. The trial will assess hearing protection benefits and cisplatin elimination metrics.
Reducing chemotherapy-induced hearing loss remains an important unmet need, particularly for patients receiving platinum-based regimens.
Read more in Fennec Pharma & U of Arizona Cancer Center Announce Study.
Key Trends Across Current Clinical Research
These developments highlight several broader themes shaping modern clinical trials:
- Growing adoption of AI-enabled screening and treatment support tools
- Continued progress in regenerative neurology and spinal cord injury recovery
- Increased focus on supportive care strategies that improve quality of life during cancer treatment
Tracking these milestones helps clinicians, sponsors, and researchers understand how innovation is progressing across multiple therapeutic areas.
